Drug Discovery
As proteins are the targets for most drugs, proteomics is important to study novel targets and understand disease mechanisms and toxicity.
Explore, how the Evosep One technology is a valuable tool for high-throughput and reliable drug discovery.
High-throughput drug discovery with the Evosep OneÂ
Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology.
The complexity in drug development has increased over the past 40 years, requiring preclinical testing, investigational new drug applications, and completed clinical testing before marketing approval from the FDA.
The overarching goal is to bring more efficient and safer treatments to the patients as quickly as possible after a thorough medical evaluation.
High-throughput and sensitive analysis on the Evosep One is a good fit when developing new drug applications or biologics license applications.
User talk
TARGETED ASSAY DEVELOPMENT FOR QUANTIFYING PROTEIN HALF-LIFE
In this user talk, Thomas Angel from the Exploratory Biomarker Assay group at GlaxoSmithKline present their work on in vivo metabolic labeling and protein turnover.
They make use of fast gradients on the Evosep One coupled to high resolution MS to enable targeted analysis of peptides from bespoke targets, facilitating quantification of label incorporation and determining protein fractional synthesis across multiple mouse tissues.
Robust and Reproducible Protein Quantification in PlasmaÂ
At Pelago Biosciences, they have stablished the Cellular Thermal Shift Assay (CETSA) in a high-throughput drug discovery pipeline with the Evosep One, enabling them to analyze a large number of compounds and unravel common or distinct pathways activation.
In this publication, they present a deep and comprehensive profiling of Staurosporine induced proteome thermal stability alteration utilizing different experiment layouts.
Ultimately, they collected data from 14 individual replicates of Staurosporine-treated K562 lysates, which allowed them to quantify more than 7500 proteins.
From this comprehensive dataset, they were able to detect 293 proteins with concentration dependent changes in thermal stability – 169 stabilized proteins (117 kinases – in blue) and 63 (11 kinases – in red) destabilized proteins.
EVOSEP WEBINAR
MEET OUR USERS and their research using targeted workflows
High-throughput drug discovery with the Evosep One
Available on demand
In this webinar we will look into how the Evosep One with high-throughput and sensitivity is a good fit when developing new drug applications or biologics license applications.
More research with Drug Discovery
Here you can see publications available on drug discovery featuring Evosep One. For a full overview of publications published using the Evosep One Technology visit our Literature room here
Title | Subject | Material | Year | Summary | Institute | Evosep method | MS instrumentation | Learn More |
---|---|---|---|---|---|---|---|---|
A tale of two tails – efficient profiling of protein degraders by specific functional and target engagement readouts | CETSA, DDA, TMT | Publication | 2020 | CETSA MS profiling | Thermo Q Exactive HF-X | |||
In-Depth Characterization of Staurosporine Induced Proteome Thermal Stability Changes | CETSA, DDA, Fractionation, TMT | Publication | 2020 | Deep CETSA MS profiling of Staurosporine | Thermo Q Exactive HF |
explore more
Find all publications, product brochures and presentations with Evosep One